Abstract:The bivalent ligand approach has been utilized not only to study the underlying mechanism of G protein-coupled receptors dimerization and/or oligomerization, but also to enhance ligand affinity and/or selectivity for potential treatment of a variety of diseases by targeting this process. Substance abuse and addiction have made both the prevention and the treatment of human immunodeficiency virus (HIV) infection more difficult to tackle. Morphine, a mu opioid receptor (MOR) agonist, can accelerate HIV infection through up-regulating the expression of the chemokine receptor CCR5, a well-known co-receptor for HIV invasion to the host cells and this has been extensively studied. Meanwhile, two research groups have described the putative MOR-CCR5 heterodimers in their independent studies. The purpose of this paper is to report the design and synthesis of a bivalent ligand to explore the biological and pharmacological process of the putative MOR-CCR5 dimerization phenomenon. The developed bivalent ligand thus contains two distinct pharmacophores linked through a spacer; ideally one of which will interact with the MOR and the other with the CCR5. Naltrexone and Maraviroc were selected as the pharmacophores to generate such a bivalent probe. The overall reaction route to prepare this bivalent ligand was convergent and efficient, and involved sixteen steps with moderate to good yields. The preliminary biological characterization showed that the bivalent compound 1 retained the pharmacological characteristics of both pharmacophores towards the MOR and the CCR5 respectively with relatively lower binding affinity, which tentatively validated our original molecular design.

Receptor Dimerization - Rationale for the Design of Bivalent Ligands

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Design of bivalent ligands targeting putative GPCR dimers

Design of multivalent ligand targeting G-protein-coupled receptors.

Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling

Design and Synthesis of a Bivalent Ligand to Explore the Putative Heterodimerization of the Mu Opioid Receptor and the Chemokine Receptor CCR5.

Structural Basis of Orientated Asymmetry in a Mglu Heterodimer

G Protein-Coupled Receptor Dimerization—What Next?

GPCR heteromers: An overview of their classification, function and physiological relevance

Development of Putative Bivalent Dicovalent Ligands for the Adenosine A1 Receptor

G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding.

A key interfacial residue identified with in-cell structure characterization of a class A GPCR dimer

Membrane-Mediated Oligomerization of G Protein Coupled Receptors and Its Implications for GPCR Function

Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.

Dopaminergic Pharmacology Revealed by Structures of Human Dopamine D3 Receptor-G I Complexes

Structural Understanding of Peptide-Bound G Protein-Coupled Receptors: Peptide-Target Interactions.

G Protein-Coupled Estrogen Receptor (Gper) Agonist Dual Binding Mode Analyses Toward Understanding Of Its Activation Mechanism: A Comparative Homology Modeling Approach

A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.

Stabilised D R G-protein coupled receptor oligomers identify multi-state β-arrestin complexes

Advances in Receptor Conformation Research: the Quest for Functionally Selective Conformations Focusing on the Β2-Adrenoceptor.